332
Participants
Start Date
March 28, 2017
Primary Completion Date
February 7, 2023
Study Completion Date
February 7, 2023
Nivolumab
Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
Placebo
Placebo consisting of sterile 0.9% sodium chloride as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
Ulster Hospital, Dundonald
Raigmore Hospital, Inverness
East Kent Hospitals University Foundation Trust, Canterbury
Northumbria Healthcare NHS Foundation Trust, Newcastle upon Tyne
Aberdeen Royal Infirmary, Aberdeen
Basildon University Hospital, Basildon
Belfast City Hospital, Belfast
Royal Bournemouth Hospital, Bournemouth
Addenbrooke's Hospital, Cambridge
Velindre Cancer Centre, Cardiff
Ninewells Hospital, Dundee
Beatson West of Scotland Cancer Centre, Glasgow
Harrogate District Hospital, Harrogate
University Hospitals Morecambe Bay, Lancaster
Leicester Royal Infirmary, Leicester
Barts Cancer Institute, London
University College London Hospitals NHS Foundation Trust, London
Wythenshawe Hospital, Manchester
Mount Vernon Cancer Centre, Northwood
Churchill Hopsital, Oxford
Southampton General Hospital, Southampton
Southend Hospital, Southend-on-Sea
Lister Hospital, Stevenage
Musgrove Park Hospital, Taunton
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
University of Southampton
OTHER